EL

Eli Lilly and Company

Every trial this sponsor leads in the registry, and everything it has published.

2,145All trials
Recruiting118
Recruited100
Not yet recruiting19
By invitation1
Completed1,740
Stopped164
Other3

238 active · 11% of this sponsor’s registry footprint

Metabolic/Endocrine/Nutrition69 trials
Oncology68 trials
Neurology28 trials
Immunology & Inflammation16 trials
Cardiovascular8 trials
Psychiatry & Addiction8 trials
Dermatology7 trials
Pain & Musculoskeletal6 trials

Not shown above: 17 Phase 1 healthy-volunteer trials.

Trials by phase

Phase 1888
Phase 2512
Phase 3550
Phase 4176
Unphased19

Pipeline by phase · 79 drugs in active development

Phase 3 · 22 drugs

Orforglipron17 trials · 7 recruitingest. Feb 2027
Brenipatide (LY3537031)15 trials · 11 recruitingest. Feb 2027
Abemaciclib (LY2835219)13 trialsest. Feb 2027
Eloralintide (LY3841136)12 trials · 9 recruitingest. Oct 2026
Retatrutide9 trialsest. Oct 2026
Donanemab8 trials · 4 recruitingest. Nov 2027
Baricitinib6 trials · 4 recruitingest. Oct 2026
Selpercatinib (LOXO-292)6 trials

Phase 2 · 17 drugs

LY4268989 (MORF-057)5 trials · 4 recruitingest. Oct 2026
LY40659673 trials · 3 recruitingest. Apr 2027
Macupatide3 trials · 2 recruitingest. Mar 2027
Eltrekibart (LY3041658)2 trials · 1 recruitingest. Dec 2027
LY39385772 trials · 1 recruitingest. Nov 2026
LY40051302 trials · 2 recruitingest. May 2027
Bimagrumab1 trial

Phase 1 · 36 drugs

LY42569843 trials · 3 recruitingest. Aug 2027
Crelosidenib (LY3410738)2 trials
LY38849612 trialsest. Mar 2031
LY39712972 trials · 1 recruitingest. Nov 2027
[Ac-225]-PSMA-62 (mCRPC)1 trialest. Sept 2027
Debecarasib (LY3962673)1 trial · 1 recruitingest. Mar 2029
LOXO-7831 trial · 1 recruitingest. Dec 2026
LY32008821 trial

Phase 4 · 4 drugs

Tirzepatide14 trials · 5 recruitingest. Nov 2026
Pirtobrutinib11 trials · 6 recruitingest. Oct 2026
Mirikizumab9 trials · 7 recruitingest. Feb 2027
Lebrikizumab (LY3650150)6 trials · 1 recruitingest. May 2027

Not counted above: 2 unphased interventions.

Active trials only, code names and brands merged. 1,740 completed trials are in the counts above but their drugs are not folded into this pipeline.

Disease landscapes · 7 of 10 curated

Breast cancer (Oncology)24 trials · 8 recruiting · 12 drugs0.8% of landscape
Type 2 diabetes (Endocrinology)15 trials · 5 recruiting · 9 drugs1.6% of landscape
Non-small cell lung cancer (Oncology)11 trials · 3 recruiting · 7 drugs0.8% of landscape
Alzheimer's disease (Neurology)8 trials · 4 recruiting · 4 drugs2.1% of landscape
Obesity (Metabolic & Nutrition)5 trials · 3 drugs0.5% of landscape
Ulcerative colitis (Gastroenterology & Hepatology)3 trials · 3 recruiting · 2 drugs1.8% of landscape
Atopic dermatitis (Dermatology)2 trials · 1 drug1.1% of landscape

Active trials judged against ten curated disease boundaries; the share compares this company's active trials with the landscape's industry-wide total. Activity outside these landscapes appears in the therapy-area split above.

Track your drug now for free

We check every one of its trials daily and tell you what moved.

  • Status changeStatus moved to completedWas recruiting · always alerts
  • Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
  • New trialNew trial registered in your scopeFirst posted within 30 days
  • Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
  • Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English
US registryClinicalTrials.gov
EU registryCTIS · Soon